Current therapeutic strategies for cognitive impairment include regulation of the cholinergic system via inhibition of acetylcholinesterase (AChE) or direct stimulation of muscarinic and nicotinic receptors, neuroprotection via glutamate-induced N-Methyl D-aspartate (NMDA) receptor overstimulation, and the use of anti-inflammatory and anti-oxidant agents [10–12]. This evidence concerns the gene ACHE and Cognitive impairment.